Literature DB >> 33421092

Behçet disease, new insights in disease associations and manifestations: a next-generation sequencing study.

M Elfishawi1, G Mossallam2, D G Augusto3, G Montero-Martin4, H de Bruin5, L Van de Pasch5, P J Norman6, E Rozemuller5, M Fernandez-Vina4, A Abrudescu7, J A Hollenbach3, K Zaky8, S Elfishawi2.   

Abstract

Behçet disease is a multi-system disease associated with human leukocyte antigen (HLA) class I polymorphism. High-resolution next-generation sequencing (NGS) with haplotype analysis has not been performed previously for this disease. Sixty Egyptian patients diagnosed according to the International Study Group (ISG) criteria for Behçet disease and 160 healthy geographic and ethnic-matched controls were genotyped for HLA class I loci (HLA-A, B, C). For HLA class II loci (DRB1, DRB3/4/5, DQA1, DQB1, DPA1, DPB1), 40 control samples were genotyped. High-resolution HLA genotyping was performed using NGS and the results were analyzed. Clinical manifestations were oral ulcers (100%), genital ulcers (100%), eye (55%) and neurological (28%) and vascular involvement (35%). HLA-B*51:08 [odds ratio (OR) = 19·75, 95% confidence interval (CI) = 6·5-79; P < 0·0001], HLA-B*15:03 (OR = 12·15, 95% CI = 3·7-50·7; P < 0·0001), HLA-C*16:02 (OR = 6·53, 95% CI = 3-14; P < 0·0001), HLA-A*68:02 (OR = 3·14, 95% CI = 1·1-8·9; P < 0·01) were found to be associated with Behçet disease, as were HLA-DRB1*13:01 and HLA-DQB1*06:03 (OR = 3·39, 95% CI = 0·9-18·9; P = 0·04 for both). By contrast, HLA-A*03:01 (OR = 0·13, 95% CI = 0-0·8; P = 0·01) and HLA-DPB1*17:01 were found to be protective (OR = 0·27, 95% CI = 0·06-1·03; P = 0·02). We identified strong linkage disequilibrium between HLA-B*51:08 and C*16:02 and A*02:01 in a haplotype associated with Behçet disease. HLA-B*51:08 was significantly associated with legal blindness (OR = 2·98, 95% CI = 1·06-8·3; P = 0·01). In Egyptian Behçet patients, HLA-B*51:08 is the most common susceptibility allele and holds poor prognosis for eye involvement.
© 2021 British Society for Immunology.

Entities:  

Keywords:  Behçet disease; epidemiology; genetics; next-generation sequencing; susceptibility

Mesh:

Substances:

Year:  2021        PMID: 33421092      PMCID: PMC7944360          DOI: 10.1111/cei.13571

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   5.732


  32 in total

Review 1.  Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies.

Authors:  Carla Maldini; Michael P Lavalley; Morgane Cheminant; Mathilde de Menthon; Alfred Mahr
Journal:  Rheumatology (Oxford)       Date:  2012-01-11       Impact factor: 7.580

Review 2.  Behçet syndrome: a contemporary view.

Authors:  Hasan Yazici; Emire Seyahi; Gulen Hatemi; Yusuf Yazici
Journal:  Nat Rev Rheumatol       Date:  2018-01-03       Impact factor: 20.543

3.  Four-digit allele genotyping of the HLA-A and HLA-B genes in Japanese patients with Behcet's disease by a PCR-SSOP-Luminex method.

Authors:  Y Itoh; H Inoko; J K Kulski; S Sasaki; A Meguro; N Takiyama; T Nishida; T Yuasa; S Ohno; N Mizuki
Journal:  Tissue Antigens       Date:  2006-05

4.  New insights of HLA class I association to Behçet's disease in Portuguese patients.

Authors:  A Bettencourt; C Pereira; L Carvalho; C Carvalho; J V Patto; M Bastos; A M Silva; R Barros; C Vasconcelos; P Paiva; L Costa; P P Costa; D Mendonça; J Correia; B M Silva
Journal:  Tissue Antigens       Date:  2008-07-08

5.  [HLA polymorphism and Behçet's disease in Moroccan population].

Authors:  N Bennani; O Atouf; N Benseffaj; C Brick; M Essakalli
Journal:  Pathol Biol (Paris)       Date:  2008-11-26

Review 6.  Is Behçet's disease a 'class 1-opathy'? The role of HLA-B*51 in the pathogenesis of Behçet's disease.

Authors:  M Giza; D Koftori; L Chen; P Bowness
Journal:  Clin Exp Immunol       Date:  2017-10-06       Impact factor: 4.330

7.  HLA class I and class II genotyping in patients with Behcet's disease: a regional study of eastern part of Turkey.

Authors:  I Pirim; M Atasoy; M Ikbal; T Erdem; C Aliagaoglu
Journal:  Tissue Antigens       Date:  2004-09

Review 8.  HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies.

Authors:  Mathilde de Menthon; Michael P Lavalley; Carla Maldini; Loïc Guillevin; Alfred Mahr
Journal:  Arthritis Rheum       Date:  2009-10-15

9.  Contribution of Hla-B51 in the susceptibility and specific clinical features of Behcet's disease in Tunisian patients.

Authors:  Amira Hamzaoui; Mohamed Habib Houman; Meriem Massouadia; Thouraya Ben Salem; Monia Smiti Khanfir; Imed Ben Ghorbel; Mohamed Miled
Journal:  Eur J Intern Med       Date:  2012-01-27       Impact factor: 4.487

Review 10.  The immunogenetics of Behçet's disease: A comprehensive review.

Authors:  Masaki Takeuchi; Daniel L Kastner; Elaine F Remmers
Journal:  J Autoimmun       Date:  2015-09-05       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.